Tucidinostat | Class I HDAC inhibitor

Available Options

Size:PriceQuantity 
5 mg$55.00
25 mg$170.00
Request Quote / Bulk / Custom Size
Product Inquiry

Tucidinostat (1616493-44-7) is a potent inhibitor of Class I HDACs (IC50’s: HDAC1 = 95 nM, HDAC2 = 160 nM, HDAC3 = 67 nM, HDAC 8 = 733 nM; also inhibits HDAC10, 78 nM).1 It increased the efficacy and persistence of CAR-T cells.2 Tucidinostat displayed efficacy against multiple types of cancer.3,4

References/Citations:

  1. Ning et al. (2012), Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity; Cancer Chemother. Pharmacol. 69 901
  2. Zhu et al. (2024), Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway; Cell Rep. 43 114065
  3. Gao et al. (2017), Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy; Anticancer Agents Med. Chem. 17 802
  4. Sun et al. (2022), Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment; Front. Pharmacol. 13 932914
1616493-44-7, chidamide, Chidamide supplier, Class I HDAC inhibitor, Tucidinostat, Tucidinostat supplier
Alternate Name:
Chidamide

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Tucidinostat (1616493-44-7) is a potent inhibitor of Class I HDACs (IC50’s: HDAC1 = 95 nM, HDAC2 = 160 nM, HDAC3 = 67 nM, HDAC 8 = 733 nM; also inhibits HDAC10, 78 nM).1 It increased the efficacy and persistence of CAR-T cells.2 Tucidinostat displayed efficacy against multiple types of cancer.3,4

References/Citations:

  1. Ning et al. (2012), Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity; Cancer Chemother. Pharmacol. 69 901
  2. Zhu et al. (2024), Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway; Cell Rep. 43 114065
  3. Gao et al. (2017), Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy; Anticancer Agents Med. Chem. 17 802
  4. Sun et al. (2022), Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment; Front. Pharmacol. 13 932914